David Redfern
David Redfern, Chief Strategy Officer, discusses the two transactions with Bristol-Myers Squibb to acquire their late-stage HIV pipeline assets and also their pre-clinical and discovery stage research assets.
David Redfern, Chief Strategy Officer, discusses the two transactions with Bristol-Myers Squibb to acquire their late-stage HIV pipeline assets and also their pre-clinical and discovery stage research assets.
